2024
Risk factors underlying racial and ethnic disparities in tuberculosis diagnosis and treatment outcomes, 2011–19: a multiple mediation analysis of national surveillance data
Regan M, Barham T, Li Y, Swartwood N, Beeler Asay G, Cohen T, Horsburgh C, Khan A, Marks S, Myles R, Salomon J, Self J, Winston C, Menzies N. Risk factors underlying racial and ethnic disparities in tuberculosis diagnosis and treatment outcomes, 2011–19: a multiple mediation analysis of national surveillance data. The Lancet Public Health 2024, 9: e564-e572. PMID: 39095133, DOI: 10.1016/s2468-2667(24)00151-8.Peer-Reviewed Original ResearchConceptsUS-born individualsNon-US-born individualsHispanic individualsTract-level povertyTract-level measuresEthnic disparitiesCensus tract levelCensus tract-level povertyEconomic segregationEvidence of disparitiesAnalysis of national surveillance dataBlack individualsTuberculosis outcomesNeighborhood-level social vulnerabilityTract levelUS-bornSocial vulnerabilityUS National Tuberculosis Surveillance SystemNational Tuberculosis Surveillance SystemHigh riskCensusNational surveillance dataTuberculosis Surveillance SystemCase managementReduce disparities
2023
Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis
Martinez L, Warren J, Harries A, Croda J, Espinal M, Olarte R, Avedillo P, Lienhardt C, Bhatia V, Liu Q, Chakaya J, Denholm J, Lin Y, Kawatsu L, Zhu L, Horsburgh C, Cohen T, Andrews J. Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis. The Lancet Public Health 2023, 8: e511-e519. PMID: 37393090, PMCID: PMC10323309, DOI: 10.1016/s2468-2667(23)00097-x.Peer-Reviewed Original ResearchConceptsTuberculosis incidenceCase detection ratioIncidence rateCase detectionHigh tuberculosis incidence ratesGlobal tuberculosis control effortsIncident tuberculosis casesTuberculosis incidence rateIncarcerated individualsTuberculosis control effortsTuberculosis case detectionTuberculosis casesNotification ratesNational incidenceTuberculosis notificationsGlobal incidenceHigh riskPrevalence estimatesNational estimatesWHO regionsIncidenceStudy periodMeta-regression frameworkTuberculosisNational Institute
2021
The escalating tuberculosis crisis in central and South American prisons
Walter KS, Martinez L, Arakaki-Sanchez D, Sequera VG, Sanabria G, Cohen T, Ko AI, García-Basteiro AL, Rueda ZV, López-Olarte RA, Espinal MA, Croda J, Andrews JR. The escalating tuberculosis crisis in central and South American prisons. The Lancet 2021, 397: 1591-1596. PMID: 33838724, PMCID: PMC9393884, DOI: 10.1016/s0140-6736(20)32578-2.Peer-Reviewed Original ResearchIncidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis
Cords O, Martinez L, Warren JL, O’Marr J, Walter KS, Cohen T, Zheng J, Ko AI, Croda J, Andrews JR. Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis. The Lancet Public Health 2021, 6: e300-e308. PMID: 33765455, PMCID: PMC8168455, DOI: 10.1016/s2468-2667(21)00025-6.Peer-Reviewed Original ResearchConceptsPrevalence of tuberculosisIncidence of tuberculosisM tuberculosis infectionIncidence rate ratiosTuberculosis infectionGeneral populationSystematic reviewSouth-East Asia RegionIncarcerated populationsPopulation-level incidenceMycobacterium tuberculosis infectionRate ratioTuberculosis Control ProgrammeLILACS electronic databasesWHO Eastern Mediterranean RegionWHO South-East Asia RegionWeb of KnowledgeCohort studyUS National InstitutesSubgroup analysisPooled estimatesHigh riskElectronic databasesPreventive interventionsTuberculosis
2020
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. The Lancet Global Health 2020, 8: e1223-e1233. PMID: 32827484, PMCID: PMC7549318, DOI: 10.1016/s2214-109x(20)30227-8.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapySecondary preventive therapyHigh-incidence settingsPost-treatment followPreventive therapyTuberculosis controlTuberculosis incidenceTreatment completionTuberculosis case findingOverall disease burdenHigh tuberculosis incidenceTuberculosis-endemic settingHigh-incidence communityFirst yearHealth system costsRecurrent tuberculosisSecondary preventionAnnual followTuberculosis treatmentDisease burdenHigh riskCase findingSingle followSuburban Cape TownPreventive interventions
2019
Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study
Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. The BMJ 2019, 367: l5894. PMID: 31649017, PMCID: PMC6812583, DOI: 10.1136/bmj.l5894.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntitubercular AgentsChildChild, PreschoolContact TracingDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceInfantInfant, NewbornIsoniazidKaplan-Meier EstimateMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPeruProspective StudiesRifampinSputumTuberculin TestTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryYoung AdultConceptsDrug-sensitive tuberculosisMultidrug-resistant tuberculosisHousehold contactsProspective cohort studySensitive tuberculosisTuberculosis infectionResistant tuberculosisCohort studyTuberculosis diseaseHigh riskDrug-resistant Mycobacterium tuberculosisIncident tuberculosis diseasePhenotypic drug resistanceDistrict Health CenterResistant Mycobacterium tuberculosisDrug-susceptible strainsDrug resistance profilesActive diseasePulmonary tuberculosisDisease progressionGuideline producersHealth centersIndex patientsEffective treatmentPatients
2018
Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogenInvestigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis
Warren JL, Grandjean L, Moore DAJ, Lithgow A, Coronel J, Sheen P, Zelner JL, Andrews JR, Cohen T. Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis. BMC Medicine 2018, 16: 122. PMID: 30071850, PMCID: PMC6091024, DOI: 10.1186/s12916-018-1111-x.Peer-Reviewed Original Research
2016
High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions
Marx FM, Floyd S, Ayles H, Godfrey-Faussett P, Beyers N, Cohen T. High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions. European Respiratory Journal 2016, 48: 1227-1230. PMID: 27390274, PMCID: PMC5512114, DOI: 10.1183/13993003.00716-2016.Peer-Reviewed Original ResearchConceptsHigh-burden settingsHigh TB prevalenceRecurrent tuberculosisExogenous reinfectionPrevalent tuberculosisTB prevalenceSuccessful treatmentHigh burdenImportant underlying mechanismHigh riskHigh incidenceControl interventionsTargeted interventionsTuberculosisUnderlying mechanismOne-thirdInterventionBurdenCape TownIndividualsReinfectionPrevalenceIncidenceDiseaseSetting
2015
Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data
Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Manjourides J, Grenfell BT, Cohen T. Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. The Journal Of Infectious Diseases 2015, 213: 287-294. PMID: 26175455, PMCID: PMC4690150, DOI: 10.1093/infdis/jiv387.Peer-Reviewed Original ResearchConceptsMDR tuberculosisDrug susceptibilityTuberculosis casesMultidrug-resistant tuberculosis (MDR-TB) transmissionCulture-confirmed diseaseHealth Center areaProspective cohort studyCapita incidenceHousehold contactsCohort studyTuberculosis riskTuberculosis transmissionSymptomatic individualsHigh riskPositive culturesNumber tandem repeatRiskEtiology
2014
How can mathematical models advance tuberculosis control in high HIV prevalence settings?
Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG, . How can mathematical models advance tuberculosis control in high HIV prevalence settings? The International Journal Of Tuberculosis And Lung Disease 2014, 18: 509-514. PMID: 24903784, PMCID: PMC4436821, DOI: 10.5588/ijtld.13.0773.Peer-Reviewed Original ResearchConceptsHigh HIV prevalence settingsHIV prevalence settingsTB-HIVTuberculosis controlPrevalence settingsHigh human immunodeficiency virus (HIV) prevalenceHuman immunodeficiency virus (HIV) prevalenceTB ModellingHealth policy makersDifficult diagnosisDisease progressionHigh riskHigh mortalityHealth systemNatural progressionVirus prevalencePublic healthProgressionMortalityPrevalenceSettingAnalysis ConsortiumDiagnosisExpert discussionGeographical heterogeneity of multidrug-resistant tuberculosis in Georgia, January 2009 to June 2011.
Jenkins HE, Gegia M, Furin J, Kalandadze I, Nanava U, Chakhaia T, Cohen T. Geographical heterogeneity of multidrug-resistant tuberculosis in Georgia, January 2009 to June 2011. Eurosurveillance 2014, 19 PMID: 24679722, PMCID: PMC4090679, DOI: 10.2807/1560-7917.es2014.19.11.20743.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBMDR-TB risk factorsTB casesRisk factorsMDR-TB incidenceMDR-TB riskMDR-TB transmissionMDR-TB casesMultidrug-resistant tuberculosisTreatment-naïve individualsMDR-TB burdenTuberculosis casesHigh riskTargeted interventionsSurveillance dataGeographical heterogeneityRegression modellingInterventionRiskRural areasCasesTuberculosisIncidencePercentageHigh risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.
Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. European Respiratory Journal 2014, 43: 1132-41. PMID: 24558181, PMCID: PMC4005038, DOI: 10.1183/09031936.00203613.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB diagnosisMDR-TB casesTB treatmentFirst-line TB drugsAmbulatory TB treatmentMDR-TB riskDrug susceptibility testingNosocomial transmissionInitial diagnosisPercentage of individualsTB drugsTuberculosis treatmentEarly treatmentHigh riskSputum specimensSurveillance databasePrevious incarcerationDrug resistanceMultidrug resistanceDiagnosisTreatmentBaseline resistanceRapid appearanceRisk
2013
Disease Mapping with Spatially Uncertain Data
Manjourides J, Cohen T, Jeffery C, Pagano M. Disease Mapping with Spatially Uncertain Data. Online Journal Of Public Health Informatics 2013, 5 PMCID: PMC3692831, DOI: 10.5210/ojphi.v5i1.4380.Peer-Reviewed Original ResearchNew TB casesDrug sensitivity testingTB casesProgrammatic dataHigh TB burdenDrug-resistant casesTB burdenIncident casesResistant casesUnderlying burdenHigh riskRoutine dataDisease acquisitionInverse probabilityTransmission hotspotsSensitivity testingNon-random sampleRiskLocation of casesReduced testingDiseaseRepresentative sampleUnadjusted dataDRTBUntested casesRisk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova
Jenkins HE, Ciobanu A, Plesca V, Crudu V, Galusca I, Soltan V, Cohen T. Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 373-380. PMID: 23407226, PMCID: PMC3710709, DOI: 10.5588/ijtld.12.0464.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsContinuity of Patient CareFemaleHumansInstitutionalizationLeast-Squares AnalysisLinear ModelsMaleMedication AdherenceMoldovaMultivariate AnalysisPatient DischargePrisonersProportional Hazards ModelsRetrospective StudiesRisk FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeTuberculosisConceptsMultidrug-resistant tuberculosisMDR-TB patientsRisk factorsHighest MDR-TB ratesDrug resistanceGreater lung pathologyMDR-TB ratesAnti-tuberculosis treatmentIndependent risk factorHuman immunodeficiency virusTB drug resistanceContinuity of careRoutine surveillance dataTuberculosis patientsResistant tuberculosisImmunodeficiency virusLung pathologyTreatment adherenceRetrospective analysisHigh riskPatientsSociodemographic factorsCommunity careSurveillance dataStudy period
2012
Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data
Manjourides J, Lin HH, Shin S, Jeffery C, Contreras C, Santa Cruz J, Jave O, Yagui M, Asencios L, Pagano M, Cohen T. Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data. Tuberculosis 2012, 92: 273-279. PMID: 22401962, PMCID: PMC3323731, DOI: 10.1016/j.tube.2012.02.003.Peer-Reviewed Original ResearchConceptsDrug sensitivity testTransmission hotspotsRetreatment casesDrug-resistant tuberculosis epidemicRisk of MDRTime of diagnosisDrug-resistant diseaseTB casesResistant diseaseTuberculosis epidemicHigh riskUntreated casesProgrammatic dataMDRTBRiskMDRHigh levelsTargeted investigationGeographic areasCasesDiseaseDiagnosisSensitivity tests
2011
Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure
Mills HL, Cohen T, Colijn C. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. Journal Of The Royal Society Interface 2011, 8: 1510-1520. PMID: 21508012, PMCID: PMC3163428, DOI: 10.1098/rsif.2011.0160.Peer-Reviewed Original ResearchConceptsTB diseaseLatent M. tuberculosis infectionEffects of IptHIV-endemic settingsActive tuberculosis diseaseIsoniazid preventive therapyIntact immune systemM. tuberculosis infectionWorld Health OrganizationPreventive therapyTB casesTuberculosis infectionTuberculosis diseaseClinical trialsEndemic settingsIPT programHigh riskLatent infectionSingle drugCommunity-wide levelRespiratory contactHIVImmune systemPopulation-level impactUse of IPT